サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1239487

脳脊髄液管理市場：タイプ別（CSFシャント、外部排液システム）、年齢層別（小児、成人）、世界の機会分析と産業予測、2021年～2031年

Cerebrospinal Fluid Management Market By Type (CSF shunts, External drainage system), By Age group (Pediatric, Adult): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 220 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
脳脊髄液管理市場：タイプ別（CSFシャント、外部排液システム）、年齢層別（小児、成人）、世界の機会分析と産業予測、2021年～2031年
出版日: 2023年01月01日
発行: Allied Market Research
ページ情報: 英文 220 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脳脊髄液管理市場は、2021年に6億7,544万米ドルと評価され、2022年から2031年にかけて4.4%のCAGRを示し、2031年には10億3,256万米ドルに達すると予測されています。

水頭症とは、脳の奥にある脳室内に液体が溜まることを指します。脳脊髄液と呼ばれる過剰な液体は、脳室のサイズを大きくし、脳を圧迫します。脳脊髄液管理装置を使用することで治療することができます。脳脊髄液管理装置には、髄液の流れを維持し、脳内の余分な液体を排出するためのシャントや外部排水システムなどの装置が含まれます。頭蓋内圧の上昇は、中枢神経系に不可逆的な損傷をもたらす可能性があります。静脈血圧や動脈血圧、衝撃圧の急性変化に対する保護機能を備えています。とはいえ、外傷、腫瘍、感染症、神経外科的処置、その他の要因で頭蓋内圧が上昇することがあります。外傷および非外傷性の原因による頭蓋内圧の上昇の管理には、外科的および非外科的な治療方法の両方が使用されることがあります。脳損傷で頭蓋内圧が上昇した患者では、頭蓋内圧をモニタリングすることで、治療に対する反応や圧力の動態を客観的に評価することができます。モニタリングには脳室内，脳実質内，クモ膜下，硬膜外などの部位があり，さまざまな装置の利点と欠点がある．

脳脊髄液管理市場の成長は、脳手術件数の増加、研究開発件数の急増、政府・民間機関による製品開発費の増加、脳脊髄液管理装置の技術進歩の増加、研究所の増加によってもたらされます。さらに、正常な脳脊髄液の循環と回転の乱れは、アルツハイマー病などの神経変性疾患、虚血性・外傷性脳損傷、多発性硬化症などの神経炎症性疾患の発症に寄与すると考えられています。したがって、脳脊髄液管理デバイスの採用が増加し、市場の成長を後押ししています。また、製薬・バイオテクノロジー研究機関の研究パイプラインの増加や、脳脊髄液の量が乱れている状態での調査研究に対する意識の高まりも、市場の成長を後押ししています。例えば、国立医学図書館の調査によると、2021年6月、インドでは2019年の2550件の入院に対し、調査期間中に687件の脳神経外科の入院があっています。また、脳神経外科で行われた手術の総数も同様の傾向を示しており、2019年の3165件の手術に対し、2020年の手術は654件にとどまっています。さらに、神経疾患にかかりやすい老年人口の増加も市場の需要に寄与しています。しかし、脳脊髄液関連疾患の治療費が高額であることが、市場の成長を阻害すると予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争の激しさ
  • 市場力学
    • 促進要因
      • 脳障害の有病率の増加
      • 高齢者人口の増加
      • CSFシャントの開発に対する需要の高まり
    • 抑制要因
      • シャントに関連する合併症
    • 機会
      • 調査開発（R&D）活動の増加
  • 市場におけるCOVID-19影響分析

第4章 脳脊髄液管理市場：タイプ別

  • 概要
    • 市場規模と予測
  • 髄液シャント
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 外部排水システム
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第5章 脳脊髄液管理市場：年齢層別

  • 概要
    • 市場規模と予測
  • 小児科
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • アダルト
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第6章 脳脊髄液管理市場：地域別

  • 概要
    • 市場規模と予測：地域別
  • 北米
    • 主な動向と機会
    • 市場規模と予測：タイプ別
    • 市場規模と予測：年代別
    • 市場規模と予測：国別
      • 米国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • カナダ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • メキシコ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
  • 欧州
    • 主な動向と機会
    • 市場規模と予測：タイプ別
    • 市場規模と予測：年代別
    • 市場規模と予測：国別
      • ドイツ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • フランス
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • 英国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • イタリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • スペイン
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • その他欧州
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
  • アジア太平洋
    • 主な動向と機会
    • 市場規模と予測：タイプ別
    • 市場規模と予測：年代別
    • 市場規模と予測：国別
      • 中国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • 日本
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • インド
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • オーストラリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • 韓国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • その他アジア太平洋地域
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
  • ラテンアメリカ・中東・アフリカ
    • 主な動向と機会
    • 市場規模と予測：タイプ別
    • 市場規模と予測：年代別
    • 市場規模と予測：国別
      • ブラジル
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • サウジアラビア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • 南アフリカ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別
      • ラテンアメリカ・中東・アフリカの残り
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：タイプ別
      • 市場規模と予測：年代別

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要企業10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2021

第8章 企業プロファイル

  • Medtronic plc
  • B. Braun Melsungen AG
  • Integra LifeSciences Holdings
  • Wellona Pharma
  • Delta Surgical
  • Spiegelberg GmbH & Co. KG
  • G. Surgiwear Ltd.
  • Moller Medical GmbH
  • Natus Medical Incorporated
  • Tokibo Co.,Ltd
図表

LIST OF TABLES

  • TABLE 01. GLOBAL CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. CEREBROSPINAL FLUID MANAGEMENT MARKET FOR CSF SHUNTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. CEREBROSPINAL FLUID MANAGEMENT MARKET FOR EXTERNAL DRAINAGE SYSTEM, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. GLOBAL CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. CEREBROSPINAL FLUID MANAGEMENT MARKET FOR PEDIATRIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. CEREBROSPINAL FLUID MANAGEMENT MARKET FOR ADULT, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. NORTH AMERICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. NORTH AMERICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. NORTH AMERICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. U.S. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. U.S. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. CANADA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. CANADA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. MEXICO CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. MEXICO CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. GERMANY CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. GERMANY CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. FRANCE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. FRANCE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. UK CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. UK CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. ITALY CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. ITALY CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. SPAIN CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. SPAIN CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. REST OF EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. REST OF EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. CHINA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. CHINA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. JAPAN CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. JAPAN CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. INDIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. INDIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. AUSTRALIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. AUSTRALIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SOUTH KOREA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SOUTH KOREA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. REST OF ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. BRAZIL CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. BRAZIL CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. SAUDI ARABIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. SAUDI ARABIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. SOUTH AFRICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. SOUTH AFRICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. REST OF LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. REST OF LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 59. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 60. MEDTRONIC PLC: PRODUCT SEGMENTS
  • TABLE 61. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 62. B. BRAUN MELSUNGEN AG: KEY EXECUTIVES
  • TABLE 63. B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
  • TABLE 64. B. BRAUN MELSUNGEN AG: PRODUCT SEGMENTS
  • TABLE 65. B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
  • TABLE 66. INTEGRA LIFESCIENCES HOLDINGS: KEY EXECUTIVES
  • TABLE 67. INTEGRA LIFESCIENCES HOLDINGS: COMPANY SNAPSHOT
  • TABLE 68. INTEGRA LIFESCIENCES HOLDINGS: PRODUCT SEGMENTS
  • TABLE 69. INTEGRA LIFESCIENCES HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 70. WELLONA PHARMA: KEY EXECUTIVES
  • TABLE 71. WELLONA PHARMA: COMPANY SNAPSHOT
  • TABLE 72. WELLONA PHARMA: PRODUCT SEGMENTS
  • TABLE 73. WELLONA PHARMA: PRODUCT PORTFOLIO
  • TABLE 74. DELTA SURGICAL: KEY EXECUTIVES
  • TABLE 75. DELTA SURGICAL: COMPANY SNAPSHOT
  • TABLE 76. DELTA SURGICAL: PRODUCT SEGMENTS
  • TABLE 77. DELTA SURGICAL: PRODUCT PORTFOLIO
  • TABLE 78. SPIEGELBERG GMBH & CO. KG: KEY EXECUTIVES
  • TABLE 79. SPIEGELBERG GMBH & CO. KG: COMPANY SNAPSHOT
  • TABLE 80. SPIEGELBERG GMBH & CO. KG: PRODUCT SEGMENTS
  • TABLE 81. SPIEGELBERG GMBH & CO. KG: PRODUCT PORTFOLIO
  • TABLE 82. G. SURGIWEAR LTD.: KEY EXECUTIVES
  • TABLE 83. G. SURGIWEAR LTD.: COMPANY SNAPSHOT
  • TABLE 84. G. SURGIWEAR LTD.: PRODUCT SEGMENTS
  • TABLE 85. G. SURGIWEAR LTD.: PRODUCT PORTFOLIO
  • TABLE 86. MOLLER MEDICAL GMBH: KEY EXECUTIVES
  • TABLE 87. MOLLER MEDICAL GMBH: COMPANY SNAPSHOT
  • TABLE 88. MOLLER MEDICAL GMBH: PRODUCT SEGMENTS
  • TABLE 89. MOLLER MEDICAL GMBH: PRODUCT PORTFOLIO
  • TABLE 90. NATUS MEDICAL INCORPORATED: KEY EXECUTIVES
  • TABLE 91. NATUS MEDICAL INCORPORATED: COMPANY SNAPSHOT
  • TABLE 92. NATUS MEDICAL INCORPORATED: PRODUCT SEGMENTS
  • TABLE 93. NATUS MEDICAL INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 94. TOKIBO CO.,LTD: KEY EXECUTIVES
  • TABLE 95. TOKIBO CO.,LTD: COMPANY SNAPSHOT
  • TABLE 96. TOKIBO CO.,LTD: PRODUCT SEGMENTS
  • TABLE 97. TOKIBO CO.,LTD: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN CEREBROSPINAL FLUID MANAGEMENT MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCEREBROSPINAL FLUID MANAGEMENT MARKET
  • FIGURE 10. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CEREBROSPINAL FLUID MANAGEMENT MARKET FOR CSF SHUNTS, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CEREBROSPINAL FLUID MANAGEMENT MARKET FOR EXTERNAL DRAINAGE SYSTEM, BY COUNTRY 2021-2031(%)
  • FIGURE 13. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CEREBROSPINAL FLUID MANAGEMENT MARKET FOR PEDIATRIC, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CEREBROSPINAL FLUID MANAGEMENT MARKET FOR ADULT, BY COUNTRY 2021-2031(%)
  • FIGURE 16. CEREBROSPINAL FLUID MANAGEMENT MARKET BY REGION, 2021
  • FIGURE 17. U.S. CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 18. CANADA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 19. MEXICO CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 20. GERMANY CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 21. FRANCE CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 22. UK CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 23. ITALY CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. SPAIN CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. REST OF EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. CHINA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. JAPAN CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. INDIA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. AUSTRALIA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SOUTH KOREA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. BRAZIL CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. SAUDI ARABIA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. SOUTH AFRICA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. REST OF LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 40. COMPETITIVE DASHBOARD
  • FIGURE 41. COMPETITIVE HEATMAP: CEREBROSPINAL FLUID MANAGEMENT MARKET
  • FIGURE 42. TOP PLAYER POSITIONING, 2021
  • FIGURE 43. MEDTRONIC PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 45. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. B. BRAUN MELSUNGEN AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 47. B. BRAUN MELSUNGEN AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 48. B. BRAUN MELSUNGEN AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 49. INTEGRA LIFESCIENCES HOLDINGS: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. INTEGRA LIFESCIENCES HOLDINGS: RESEARCH & DEVELOPMENT EXPENDITURE, 2019-2021
  • FIGURE 51. INTEGRA LIFESCIENCES HOLDINGS: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. INTEGRA LIFESCIENCES HOLDINGS: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 53. NATUS MEDICAL INCORPORATED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. NATUS MEDICAL INCORPORATED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 55. NATUS MEDICAL INCORPORATED: REVENUE SHARE BY REGION, 2021 (%)
目次
Product Code: A10924

The Cerebral Spinal Fluid Management Market valued for $675.44 million in 2021 and is estimated to reach $1,032.56 million by 2031, exhibiting a CAGR of 4.4% from 2022 to 2031.  

Hydrocephalus refers to the buildup of fluid in the ventricles deep within the brain. The excess fluid called cerebral spinal fluid increases the size of the ventricles and puts pressure on the brain. It can be treated with the use of cerebral spinal fluid management devices. Cerebrospinal fluid (CSF) management devices involve the devices such as shunts and external drainage systems to maintain the flow of CSF and drain excess fluid from the brain. Increased intracranial pressure can result in irreversible injury to the central nervous system. It provides protection against acute changes in venous and arterial blood pressure or impact pressure. Nevertheless, trauma, tumors, infections, neurosurgical procedures, and other factors can cause increased intracranial pressure. Both surgical and nonsurgical therapeutic modalities can be used in the management of increased intracranial pressure attributable to traumatic and non-traumatic causes. In patients with cerebral injury and increased intracranial pressure, monitoring of the intracranial pressure can provide an objective measure of the response to therapy and the pressure dynamics. Intraventricular, intraparenchymal, subarachnoid, and epidural sites can be used for monitoring, and the advantages and disadvantages of the various devices available. 

The growth of the cerebral spinal fluid management market is driven by increase in the number of brain surgeries, surge in number of research and development activities, rise in expenditure on the product development by the government & private organizations and increase in the technological advancements of the cerebral spinal fluid management devices and increase in the number of research laboratories. Moreover, the disruption of normal cerebral spinal fluid circulation and turnover is believed to contribute to the development of many neurodegenerative conditions such as Alzheimer's disease, ischemic and traumatic brain injury, and neuroinflammatory conditions such as multiple sclerosis. Hence, increase in the adoption of cerebral spinal fluid management devices boosts the growth of the market. In addition, increase in the research pipeline among the pharmaceutical and biotechnology research organizations and surge in awareness about research studies on the conditions of disrupted volume of cerebral spinal fluid foster the growth of the market. For instance, according to the study of National Library of Medicine, in June 2021, there were 687 neurosurgery admissions in India during the study period compared with 2550 admissions in 2019. The total number of surgeries performed in neurosurgery also showed a similar trend, with only 654 surgeries in 2020 compared with 3165 surgeries in 2019. Moreover, increase in the geriatric population which are more prone to the neurological disorders are also contributing in the demand of the market. However, the high cost of the treatment for cerebral spinal fluid related diseases is expected to hinder the growth of the market. 

The cerebral spinal fluid management market is segmented on the basis of type, age group and region. On the basis of type, the market is bifurcated into CSF shunts and external drainage system. On the basis of age group, the market is classified into pediatric and adult. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major companies profiled in the report include: B. Braun Melsungen AG, Delta Surgical, G. SURGIWEAR LTD, Integra Lifesciences Holdings, Medtronic plc, Moller Medical GMBH, Natus Medical Incorporated, Spiegelberg GmbH & Co. KG, Tokibo Co., Ltd., and Wellong Pharma. 

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cerebral spinal fluid management market analysis from 2021 to 2031 to identify the prevailing cerebral spinal fluid management market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cerebral spinal fluid management market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cerebral spinal fluid management market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • CSF shunts
  • External drainage system

By Age group

  • Pediatric
  • Adult

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • B. Braun Melsungen AG
  • Delta Surgical
  • Spiegelberg GmbH & Co. KG
  • Moller Medical GmbH
  • Tokibo Co.,Ltd
  • Medtronic plc
  • G. Surgiwear Ltd.
  • Integra LifeSciences Holdings
  • Wellona Pharma
  • Natus Medical Incorporated

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in the prevalence of brain disorders
      • 3.4.1.2. Increase in the geriatric population
      • 3.4.1.3. Rise in demand for development in the CSF shunts
    • 3.4.2. Restraints
      • 3.4.2.1. Complications related to the shunts
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in the of research and developments (R&D) activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. CSF shunts
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. External drainage system
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Pediatric
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Adult
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: CEREBROSPINAL FLUID MANAGEMENT MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Type
    • 6.2.3. Market size and forecast, by Age group
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Type
      • 6.2.4.1.3. Market size and forecast, by Age group
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Type
      • 6.2.4.2.3. Market size and forecast, by Age group
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Type
      • 6.2.4.3.3. Market size and forecast, by Age group
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Type
    • 6.3.3. Market size and forecast, by Age group
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Type
      • 6.3.4.1.3. Market size and forecast, by Age group
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Type
      • 6.3.4.2.3. Market size and forecast, by Age group
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Type
      • 6.3.4.3.3. Market size and forecast, by Age group
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Type
      • 6.3.4.4.3. Market size and forecast, by Age group
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Type
      • 6.3.4.5.3. Market size and forecast, by Age group
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Type
      • 6.3.4.6.3. Market size and forecast, by Age group
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Type
    • 6.4.3. Market size and forecast, by Age group
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. China
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Type
      • 6.4.4.1.3. Market size and forecast, by Age group
      • 6.4.4.2. Japan
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Type
      • 6.4.4.2.3. Market size and forecast, by Age group
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Type
      • 6.4.4.3.3. Market size and forecast, by Age group
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Type
      • 6.4.4.4.3. Market size and forecast, by Age group
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Type
      • 6.4.4.5.3. Market size and forecast, by Age group
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Type
      • 6.4.4.6.3. Market size and forecast, by Age group
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Type
    • 6.5.3. Market size and forecast, by Age group
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Type
      • 6.5.4.1.3. Market size and forecast, by Age group
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Type
      • 6.5.4.2.3. Market size and forecast, by Age group
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Type
      • 6.5.4.3.3. Market size and forecast, by Age group
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Type
      • 6.5.4.4.3. Market size and forecast, by Age group

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2021

CHAPTER 8: COMPANY PROFILES

  • 8.1. Medtronic plc
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. B. Braun Melsungen AG
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
  • 8.3. Integra LifeSciences Holdings
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Wellona Pharma
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
  • 8.5. Delta Surgical
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
  • 8.6. Spiegelberg GmbH & Co. KG
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
  • 8.7. G. Surgiwear Ltd.
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
  • 8.8. Moller Medical GmbH
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
  • 8.9. Natus Medical Incorporated
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Tokibo Co.,Ltd
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio